MARKET

STRO

STRO

Sutro Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.67
-0.23
-2.32%
Opening 13:07 04/07 EDT
OPEN
10.16
PREV CLOSE
9.90
HIGH
10.30
LOW
9.63
VOLUME
7.02K
TURNOVER
--
52 WEEK HIGH
12.75
52 WEEK LOW
6.00
MARKET CAP
223.37M
P/E (TTM)
-3.9829
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average STRO stock price target is 19.86 with a high estimate of 23.00 and a low estimate of 16.00.

EPS

STRO News

More
  • $110M injection powers up Peninsula vaccine maker but not for COVID-19
  • American City Business Journals · 03/26 14:20
  • SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
  • PR Newswire · 03/26 12:00
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Sutro Biopharma EPS beats by $0.05, beats on revenue
  • seekingalpha · 03/16 16:05

Industry

Biotechnology & Medical Research
0.00%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Symbol
Price
%Change

About STRO

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.
More

Webull offers kinds of Sutro Biopharma Inc stock information, including NASDAQ:STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions.